Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, One-sequence Crossover Study to Determine the Effects of Multiple Doses of Elinzanetant on the Pharmacokinetics of Rosuvastatin in Healthy Participants

NCT04889287 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT04889287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04889287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, One-sequence Crossover Study to Determine the Effects of Multiple Doses of Elinzanetant on the Pharmacokinetics of Rosuvastatin in Healthy Participants
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
May 26, 2021
Completion date
September 29, 2021
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

vasomotor symptoms as a sex hormone-dependent disorder in women and men